Key clinical point: A higher dose of crizanlizumab shows a residual benefit for sickle cell patients after ceasing therapy.
Major finding: Vaso-occlusive crisis rates were 2.7 per year for the 5 mg/kg crizanlizumab group and 4 per year for the 2.5 mg/kg crizanlizumab group at 1 year after the end of treatment.
Study details: A multicenter, retrospective, noninterventional follow-up study of 48 sickle cell disease patients who completed the SUSTAIN trial.
Disclosures: Dr. Shah reported a financial relationship with Novartis, which is developing crizanlizumab.
Shah N et al. FSCDR 2019, Abstract JSCDH-D-19-00031.